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Antagonists of the C-type lectin DC-SIGN are promising therapeutic agents against viruses and 
bacteria. The development of glycomimetics ligands for DC-SIGN has so far proved to be 
challenging, since this membrane-protein presents four carbohydrate-binding domains (CRD) 
that specifically recognize mannose and fucose. In the recent past, we were able to develop 
inhibitors mimicking the minimal natural epitope Manα(1,2)Man using a mannoside with 
conformationally restricted dimethyl cycloexandicarboxylate-based aglycons designed to 
exploit the high enzymatic stability and to generate multivalent or solid supported systems as 
potent lectin ligands. Herein we describe the innovative synthesis of a different class of 
pseudodisaccharides, mimic of the natural Manα(1,2)Man moiety, characterized by the 
presence of a real D-carbamannose unit instead of a simpler mimic structure. Their chemical 
synthesis and biological activity using an SPR inhibition assay are reported. These 
pseudodisaccharides display inhibition values similar to those of the natural disaccharide 
Manα(1,2)Man, with a good affinity for DC-SIGN and can be considered as possible 
candidates for further structural modifications towards improved inhibitors. 
 
 
Introduction 
A broad range of biological processes including cellular 
adhesion, signaling, migration and infection are mediated by 
carbohydrate-lectin interactions.1-4 In this framework, DC-
SIGN (Dendritic Cell-Specific Intercellular adhesion molecule-
3 (ICAM-3)-Grabbing Non-integrin) is a C-type lectin involved 
in the recognition of viruses and pathogens at the mucosal 
level. In particular the interaction between gp120 on the surface 
of HIV-1 and DC-SIGN allows the delivery of the virus to 
tissues rich in CD4+ T cells, such as lymphoid organs, playing 
therefore a crucial role in the infection process at the mucosal 
level.5,6 The main carbohydrate ligand present on gp120 and 
recognized by the DC-SIGN carbohydrate-binding domains 
(CRDs) is the high mannose glycan Man9(GlcNAc)2 (Man9, 1, 
Figure 1). Therefore, derived glycomimetic structures can 
inhibit DC-SIGN action and are of high interest against HIV 
infections as antiviral agents.7-17 Notably, the 1,2-mannobioside 
disaccharide unit, Manα(1,2)Man 2 (Figure 1), contained in all 
three arms D1, D2 and D3 of Man9, is one of the minimal 
epitopes for binding to DC-SIGN. To underline the efficiency 
of this epitope and the importance of polyvalent systems, the 
incorporation of the natural 1,2-mannobioside into gold 
glyconanoparticles (Au-GNPs) increases the inhibitory activity 
by more than four orders of magnitude, compared to that of the 
monovalent disaccharide.18 We previously reported that 
disaccharide mimetics 3a-c (Figure 1) show three dimensional 
structure and conformational behavior comparable to those of 
Manα(1,2)Man 2 and display a micromolar activity against 
DC-SIGN mediated Ebola viral infection, to demonstrate for 
the first time that DC-SIGN antagonism by small molecules 
might be used to inhibit viral transfection mediated by DC-
SIGN.10,17,19 
 
 
Fig. 1 High mannose glycan Man 9(GlcNAc) 2  1, minimal epitope 
Manα(1,2)Man  2 and chemical structure of disaccharide mimetics 3a-c. 
Herein, we describe the innovative synthesis of 
pseudodisaccharides 4 and 5 (Figure 2), real carba analogues of 
the natural disaccharide epitope 2, and their biological 
evaluation as prospective DC-SIGN ligands. In our approach, 
the non reducing portion of the natural disaccharide 
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Manα(1,2)Man is replaced by a carbasugar, in view of an 
improved drug-like character of the resulting glycomimetic 
compared to the natural carbohydrate. Indeed, sugar mimics are 
generally more soluble and membrane penetrant, less 
hydrophilic and less metabolically labile than the sugars 
themselves.20 
 
 
Fig. 2 Chemical structures of pseudodisaccharides 4 and 5 real carba analogues 
of epitope 2. 
 
Results and discussion 
Synthesis of pseudodisaccharides 4 and 5.  
 
The stereoselective synthesis of pseudodisaccharides 4 and 5 
proceeds through the construction of skeleton 8 (Scheme 1) by 
glycosylation of the new carbamannose glycosyl acceptor 7 
with tetrabenzoyl mannose trichloroacetimidate 6 as typical 
glycosyl donor.21 
 
 
Scheme 1 Stereoselective synthesis of skeleton 8. 
Two carbamannose units 15 and 16, carrying either acetyl or 
benzyl protecting groups, were prepared and studied in this 
reaction.  Both were  prepared starting from the pivotal carba 
epoxy diol 11 obtained from m-CPBA epoxidation of 
cyclohexene 10  in turn prepared from tri-O-acetyl-D-glucal 
9,22 as shown in Scheme 2. 
The allyl alcohol 10 is epoxidized stereoselectively by 
MCPBA, which reacts with the double bond face in syn to the 
allylic hydroxy group.23,24 Key epoxide 11 was then separately 
elaborated to give tri-O-benzyl-5a-carba-β-epoxide (+)-
1425 upon treatment with NaH/BnBr in DMF, or debenzylated 
at C(6), under reductive conditions with H2/(10%)Pd-C, to 
afford β-epoxy triol 12 which was  in situ acetylated 
(Ac2O/Py), to give tri-O-acetyl-5a-carba-β-epoxide (+)-1325 
(Scheme 2). Epoxides (+)-13 and (+)-14 represent the 
carbaglycosylating agents which were subjected to ring 
opening reaction with freshly prepared 1.3M 2-azido-1-ethanol 
in CH2Cl2 26 in the presence of a catalytic amount of Cu(OTf)2 
as the Lewis acid catalyst.27 In accordance with reports by 
Ogawa and Cumpstey 28,29 on the behavior of 1,2-epoxides with 
β-manno configuration like (+)-13 and (+)-14, nucleophilic 
attack exclusively occurs in a trans-diaxial fashion, at the less 
sterically hindered and more electronically favored oxirane 
C(1) carbon. This way, the corresponding 2-azido-1-ethoxy-
cyclohexanol derivatives (+)-15 from (+)-13,   
 
Scheme 2 Stereoselective synthesis  of carbamannose glycosyl acceptor 15 and 
16. 
  
and (+)-16 from (+)-14, are obtained through a completely 
regio- and stereoselective ring opening process.  
 
 
Scheme 3 Stereoselective synthesis of glycoconjugates (-)-4 and (+)-5. 
Glycosylation reaction of glycosyl acceptors (+)-15 and (+)-16 
by the typical mannosyl donor 6 was successfully carried out in 
standard conditions (TMSOTf in CH2Cl2, -20 °C, 2h), to afford 
glycoconjugates (-)-17 and (-)-18 in a completely α-
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stereoselective fashion. Catalytic hydrogenolysis of (-)-18 
reduced the azido functionality and removed the benzyl 
protecting groups to afford pseudodisaccharide (-)-19. 
Subsequent Zemplén deprotection provided the final 
pseudodisaccharide (+)-5 with a α-aminoethoxy chain at 
pseudoanomeric C(1) in 69% yield after recrystallization from 
i-Pr2O. On the other hand, Zemplén deprotection of 
glycoconjugate (-)-17, afforded the α-azidoethoxy 
pseudodisaccharide (-)-4 in 88% yield (Scheme 3). 
Preparation of pseudodisaccharides (-)-4 and (+)-5 represents 
the first example of stereoselective synthesis of real carba 
analogues of minimal natural epitope Manα(1,2)Man thus, their 
biological activity as DC-SIGN antagonists was evaluated 
using an inhibition assay based on Surface Plasmon Resonance 
(SPR) technique. 
 
 
DC-SIGN inhibition assays 
 
The affinity of the newly synthesized sugar conjugates 4 and 5 
for DC-SIGN was tested by competition experiments using 
surface plasmon resonance (SPR), as previously described.11 A 
CM4 sensorchip was functionalized with mannosylated Bovine 
Serum Albumine (BSA-Mannotriose) and a fixed amount of the 
extracellular domain of DC-SIGN was injected over the surface 
with increasing concentrations of ligands. The natural 1,2-
mannobioside 2 and its mimic 3 were used as control. From the 
inhibition curves (Fig. 3) and according to 4-parameter model, 
an IC50 of about 1 mM  was estimated for all the compounds. 
These data show that the new pseudodisaccharides (+)-5 and (-
)-4 have inhibitory potency similar to the natural disaccharide 
Manα1-2Man,. The IC50, extracted from inhibition curves are 
964±14.6 µM for 2, 941±20.2 µM for 3, 1467±32.1 µM for 4 
and 1453±30.6 µM for 5. Thus, taking into account their 
enzymatic stability, (+)-5 and (-)-4 could be considered as 
possible candidates to prepare multivalent systems to be used as 
inhibitors of viral infection. 
 
 
 
Fig. 3 Inhibition of DC-SIGN extracellular domain (DC- SIGN ECD) binding to immobilized mannosylated-bovine serum albumin (BSA) using surface plasmon 
resonance (SPR). A and B: Sensorgrams of DC-SIGN ECD inhibition by increasing concentrations of compound 4 and 5, respectively, from 0 µM to 5000 µM. C. 
Comparison of the inhibitory potency of 2 (), 3 (), 4 (), and 5 () toward the DC-SIGN ECD mannosylated-BSA interaction determined by competition assays.   
Conclusions  
We have successfully planned and achieved the innovative 
stereospecific synthesis of the two glycoconjugates (-)-4  and 
(+)-5, which were intended to represent mimics of the natural 
Manα(1,2)Man moiety, characterized by the presence of a real 
D-carbamannose unit. These glycoconjugates were designed to 
mime the minimal natural epitope Manα(1,2)Man of the high 
mannose glycan Man9(GlcNAc)2, which is principal 
carbohydrate ligand recognized by the DC-SIGN. The 
biological assays evaluated using an inhibition (binding 
affinity?) assay based on Surface Plasmon Resonance (SPR) 
technique, displayed a remarkable activity of new 
pseudodisaccharides (-)-4 and (+)-5 having inhibitory potency 
similar to the natural disaccharide Manα1-2Man. These results 
confirm the validity of the DC-SIGN antagonism by small 
molecules and pave the way to more extensive studies of 
enzymatically stable glycoconjugates that are useful to prepare 
efficient multivalent systems as DC-SIGN inhibitors. 
 
Experimental 
Materials and methods 
 
 
 
All solvents and chemicals were used as purchased without 
further purification. Chromatographic separations were 
performed on silica gel columns by flash (Kieselgel 40, 0.040–
0.063 mm; Merck) or by automated chromatography with 
Isolera® Biotage. Reactions were followed by thin-layer 
chromatography (TLC) on Merck aluminum silica gel (60 F254) 
sheets that were visualized under a UV lamp. Evaporation was 
performed in vacuo (rotating evaporator). Sodium sulfate was 
always used as the drying agent. Melting points were 
determined with a Kofler hot-stage apparatus and are 
uncorrected. Optical rotations were measured with a ATAGO 
AP-300 Automatic Polarimeter at 25°C. Proton (1H) and carbon 
(13C) NMR spectra were obtained with a Bruker Avance 250 
MHz spectrometer using the indicated deuterated solvents. 
Chemical shifts are given in parts per million (ppm) (δ relative 
to residual solvent peak for 1H and 13C). FTIR spectra were 
obtained with a IR Cary 600 FTIR (Agilent 
Tecnologies).Yields refer to isolated and purified products. 
High-resolution mass spectrometry (HRMS) analysis were 
performed using a Waters Xevo® G2-S QTof at Mass 
Spectrometry facility, PCN-ICMG of Grenoble. Compounds 
are dissolved in 1:1 acetonitrile/water (concentration 10E-5 M).  
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Synthetic procedures 
6-O-Benzyl-1,2-anhydro-5a-carba-β-D-mannopyranose (11).  
MCPBA (0.627 g, 3.64 mmol, 1.2 equiv) was added to a 
solution of trans diol 1023 (0.709 g, 3.03 mol, 1.0 equiv) in 
anhydrous CH2Cl2 (17 mL) at 0°C and the reaction mixture 
was stirred at room temperature. After 18h, the reaction was 
diluted with CH2Cl2, the organic phase was washed with 10% 
aqueous Na2S2O3, saturated aqueous NaHCO3 and brine, dried 
(Na2SO4) and concentrated to afford a crude reaction product 
(0.585 g), which was subjected to a flash chromatography. 
Elution with 3:7 hexane/AcOEt mixture afforded β epoxide 11 
(0.438 g, 59% yield), pure as a white solid: mp 86-88 °C. Rf = 
0.13 (3:7 hexane/AcOEt). [α]20D +8.03 (c 0.61, CHCl3). FTIR 
(neat) ν 3360.2, 3255.3, 3026.3, 2920.5, 2852.6, 1453.5, 
1362.3, 1257.7, 1112.6, 1057.9, 1015.3, 933.3, 731.7, 695.4 
cm-1. 1H NMR (250 MHz; CDCl3) δ 7.20 – 7.43 (m, 5H; Ar), 
4.54 (d, J = 12.0 Hz, 1H; benzylic), 4.48 (d, J = 12.0 Hz, 1H; 
benzylic), 3.84 (dd, J = 8.2, 1.7 Hz, 1H; H3), 3.61 (dd, J = 10.2, 
8.3 Hz, 1H; H4), 3.52 (dd, J = 9.2, 4.8 Hz, 1H; H6), 3.47 (dd, J 
= 9.2, 4.8 Hz, 1H; H6’), 3.37 (ddd, J = 4.0, 1.7, 0.6 Hz, 1H; 
H2), 3.27 (t, J = 4.3 Hz, 1H; H1), 2.00 –2.12 (m, 1H; H5aα), 
1.79 – 1.95 (m, 1H; H5), 1.73 (dd, J = 14.2, 11.2 Hz, 1H; H5aβ). 
13C NMR (75 MHz; CDCl3) δ 137.84, 128.63, 127.99, 127.78, 
74.64, 73.52, 73.11, 72.24, 56.64, 53.30, 38.90, 26.39. 
 
3,4,6-tri-O-benzyl-1,2-anhydro-5a-carba-β-D-
mannopyranose (14).25 
A 60% dispersion of NaH (0.374 g, 9.36 mmol, 4.0 equiv) was 
added to a solution of β epoxide 11 (0.584 g, 2.34 mmol, 1.0 
equiv) in anhydrous DMF (8 mL) at 0°C and the reaction 
mixture was stirred at the same temperature for 30 minutes and 
then at room temperature for 30 minutes. After cooling at 0°C, 
BnBr (0.70 mL, 5.86 mmol, 2.5 equiv) was added dropwise and 
the solution was stirred 2 h at room temperature. Dilution with 
Et2O and ice and evaporation of the washed (brine) and dried 
(Na2SO4) organic solution afforded a crude reaction mixture 
(0.920 g), which was subjected to a flash chromatography. 
Elution with an 8:2 hexane/AcOEt mixture afforded tri-O-
bernzyl β epoxide 14 (0.740 g, 73% yield), pure as a white 
solid. mp 53-55 °C. Rf = 0.24 (8:2 hexane/AcOEt). [α]20 D 
+32.7 (c 0.81, CHCl3). FTIR (neat) ν 3025.0, 2913.9, 2852.0, 
1946.5, 1873.9, 1744.0, 1453.3, 1366.2, 1102.3, 1081.5, 
1023.5, 930.9, 737.6, 695.5 cm-1. 1H NMR (250 MHz, CDCl3) 
δ 7.27-7.45 (m, 14H; Ar), 7.20-7.25 (m, 1H; Ar), 4.84 (d, J 
=10.4 Hz, 1H; benzylic), 4.82 (s, 2H; benzylic), 4.52 (d, J 
=10.4 Hz, 1H; benzylic), 4.46 (s, 2H; benzylic), 3.83 (dd, J = 
8.1, 1.9 Hz, 1H; H3), 3.65 (dd, J =10.9, 8.1 Hz, 1H; H4), 3.45-
3.55 (m, 2H; H6 + H6’), 3.34 (dd, J = 4.1, 1.8 Hz, 1H; H2), 
3.26 (t, J = 3.9 Hz, 1H; H1), 1.97 -2.20 (m, 2H; ; H5aα + 
H5aβ), 1.90-1.63 (m, 1H; H5). 
13C NMR (75 MHz, CDCl3) δ 139.1, 139.0, 138.9, 128.8, 
128.7, 128.5, 128.3, 128.1, 128.0, 127.9, 81.9, 78.2, 75.6, 73.5, 
72.8, 70.5, 55.7, 53.9, 40.3, 27.4. 
 
(2-azidoethyl)-3,4,6-tri-O-benzyl-5a-carba-α-D-
mannopyranoside (16). 
Tri-O-bernzyl β epoxide 14 (0.370 g, 0.859 mmol, 1 equiv) was 
dissolved in a solution 1.3 M 2-azido-1-ethanol in CH2Cl2 (2.65 
mL, 3.44 mmol, 4.0 equiv) freshly prepared25 and Cu(OTf)2 (0.124 
g, 0.344 mmol, 0.4 equiv) was added. The reaction mixture was 
stirred for 18 h at room temperature. Dilution with CH2Cl2 and 
evaporation of the washed (1:1 NaHCO3/NH4Cl mixture and brine) 
and dried (Na2SO4) organic solution afforded a crude reaction 
mixture (0.363 g) which was subjected to a flash chromatography. 
Elution with 7:3 hexane/AcOEt mixture afforded product 16 (0.304 
g, 68% yield), pure as a pale yellow liquid. Rf = 0.50 (7.3 
hexane/AcOEt);  [α]20D +22.34 (c. 0.67, CHCl3). FTIR (neat) ν 
3449.6, 2927.2, 2871.8, 2103.9, 1737.6, 1284.4, 1242.6, 1109.5, 
1048.3, 993.4, 731.3, 696.8 cm-1. 1H NMR (250 MHz; CDCl3) δ 
7.20-7.40 (m, 15H; Ar), 4.83 (d, J = 10.9 Hz, 1H; benzylic), 4.72 (d, 
J = 11.5 Hz, 1H; benzylic), 4.66 (d, J = 11.5 Hz, 1H; benzylic), 4.51 
(d, J = 10.9 Hz, 1H; benzylic), 4.47 (s, 2H; benzylic), 4.13 (t, J = 3.4 
Hz, 1H; H1), 3.80 (dd, J = 9.0, 3.0 Hz, 1H; H2), 3.45-3.75 (m, 6H), 
3.18-3.39 (m, 2H; ; H6 + H6’), 1.95-2.14 (m, 1H; ; H5), 1.85-1.92 
(m, 2H; H5aα + H5aβ). 
13C NMR (63 MHz, CDCl3) δ 139.11, 138.89, 138.53, 128.76, 
128.68, 128.52, 128.51, 128.12, 128.11, 128.01, 127.74, 127.68, 
127.64, 127.18, 82.39, 77.85, 77.08, 75.09, 73.18, 72.84, 70.59, 
69.61, 68.27, 51.06, 37.37, 26.94. 
 
(2-azidoethyl)-2-O-[2’,3’,4’,6’-tetra-O-benzoyl-α-D 
mannopyranosyl]-3,4,6-tri-O-benzyl-5a-carba-α-D-
mannopyranoside (18). 
Trichloroacetimidate 621 (0.208 g, 0.281 mmol, 1.3 equiv) and 
carbamannoside 16 (0.112 g, 0.216 mmol, 1.0 equiv) were dissolved 
in distilled toluene (2.0 mL) and dried overnight under vacuum. Acid 
washed molecular sieves AW 300 were activated under vacuum and 
added to the reagents. The mixture was dissolved in dry CH2Cl2 (2.5 
mL), catalytic amount of TMSOTf (7.8 μL, 0.0432 mmol, 0.2 equiv) 
was added under nitrogen at -20°C and the reaction mixture was 
stirred at the same temperature for 3h. Et3N (20.0 μL) was added 
and the mixture was diluted with CH2Cl2 and filtered through a 
Celite® pad. Evaporation of the solvent afforded a crude product 
(0.290 g), which was subjected to a flash chromatography. Elution 
with a 7:3 hexane/acetone mixture afforded the O-protected 
pseudomannobioside 18 (0.208 mg, 88% yield), pure as a white 
solid. m.p. 40-42°C. Rf = 0.22 (7:3 hexane/acetone); [α]20D -23.0 (c 
0.63, CHCl3). FTIR (neat) ν 3350.1, 3294.9, 3069.3, 2961.0, 2875.4, 
2106.4, 1724.0, 1601.0, 1450.7, 1259.8, 1094.9, 1065.8, 1026.6, 
825.9, 707.9 cm-1. 1H NMR (250 MHz, CDCl3) δ 8.01-8.16 (m, 5H, 
Ar), 7.92-8.00 (m, 2H, Ar), 7.70-7.90 (m, 2H, Ar), 7.03-7.69 (m, 
26H, Ar), 6.04 (t, J = 9.5 Hz, 1H, H4’), 5.85-5.94 (m, 2H, H2’+H3’), 
5.45 (s, 1H, Hanomeric), 4.39-4.92 (m, 9H, benzylic + H5’ + H6’a+ 
H6’b), 4.22 (d, J = 4.2 Hz, 1H, H2), 3.78-3.86 (m, 2H, H3 + 
HCH2CH2N3), 3.68-3.75 (m, 1H, H1), 3.49-3.65 (m, 3H, 
HCH2CH2N3), 3.30-3.41 (m, 1H, H4), 3.07-3.25 (m, 2H, H6a + 
H6b), 1.83-2.16 (m, 3H, H5 + H5aα + H5aβ).   
13C NMR (CDCl3) δ 166.31, 165.73, 165.52, 165.24, 138.96, 
138.92, 138.59, 133.58, 133.27, 130.01, 129.89, 129.64, 129.37, 
129.09, 128.69, 128.61, 128.44, 127.83, 127.64, 127.56, 98.90, 
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76.25, 75.11, 73.10, 70.78, 70.40, 70.13, 69.54, 67.99, 67.35, 63.39, 
50.91, 37.71, 27.72. 
(2-aminoethyl)-2-O-[2’,3’,4’,6’-tetra-O-benzoyl-α-D-
mannopyranosyl]-5a-carba-α-D-mannopyranoside (19). 
Pseudomannobioside 18 (0.080 g, 0.073 mmol, 1.0 equiv) was 
dissolved in a 4:1 MeOH/anhydrous DMF mixture (2.0 mL) and 
10% Pd-C (0.080 g) was added. The reaction mixture was 
hydrogenated (1 bar) at room temperature under hydrogen saturated 
atmosphere until reduction of the azide group and deprotection of the 
benzyl groups were achieved, monitoring by analytical TLC (8:2 
CH2Cl2/MeOH). After 18 h the mixture was diluted with MeOH and 
filtered through a Celite® pad. The evaporation of the solvent 
afforded a crude reaction product (0.035 g) which was further 
diluted with MeOH and filtered off using syringe filter, to remove 
the residue coal. Evaporation of the solvent afforded a white solid, 
which was recrystallized from (i-Pr)2O to yield pure 1,2-
pseudomannobioside 19 (0.031 g, 53% yield), as a yellow solid: mp: 
38-39 °C. Rf = 0.3 (8:2 CH2Cl2/MeOH + 0.1% Et3N); [α]20D -34.85 
(c 0.68, MeOH). FTIR (neat) ν 3377.6, 3072.1, 2951.0, 2782.8 
1721.2, 1656.4, 1592.8, 1437.7, 1297.2, 1256.9, 1161.3, 1082.4, 
1066.3, 1018.5, 857.5, 697.4 cm-1. 1H NMR (250 MHz, CD3OD) δ 
8.06-8.16 (m, 2H, Ar), 7.88-8.03 (m, 4H, Ar), 7.22-7.80 (m, 14H, 
Ar), 6.11 (t, J = 9.8 Hz, 1H, H4’), 5.89-5.97 (m, 1H, H2’), 5.84 (dd, 
J = 10.2, 3.2 Hz, 1H, H3’), 5.48 (d, J = 1.4 Hz, 1H, Hanomeric), 
4.77 (dd, J = 13.4, 3.9 Hz, 1H, H5’), 4.47-4.58 (m, 2H, H6’a + 
H6’b), 4.23-4.26 (m, 1H, H2), 3.90-3.97 (m, 1H, H1) 3.45-3.89 (m, 
6H, H3 + H4 + H6a + H6b + OCH2), 3.07-3.12 (m, 2H, CH2NH2), 
2.00-2.13 (m, 1H, H5), 1.72-1.89 (m, 2H, H5aα + H5aβ). 13C NMR 
(63 MHz, CD3OD) δ 167.53, 167.01, 166.79, 166.54, 134.78, 
134.74, 134.57, 134.55, 131.12, 130.76, 130.71, 130.69, 130.60, 
130.51, 130.30, 130.27, 129.84, 129.78, 129.63, 129.47, 101.30, 
80.54, 78.24, 74.20, 72.33, 71.71, 71.46, 70.77, 68.31, 66.16, 64.34, 
63.92, 40.91, 40.46, 27.79 
(2-aminoethyl)-2-O-(α-D-mannopyranosyl)-5a-carba-α-D-
mannopyranoside (5). 
A solution 1M of MeONa in MeOH (65.0 μL, 0.065 mmol, 1.5 
equiv) was added to a solution of 1,2-pseudomannobioside 19 (0.034 
g, 0.043 mmol, 1.0 equiv) in MeOH (0.8 mL). The reaction mixture 
was stirred for 12h monitoring by TLC (8:2 CH2Cl2/MeOH). The 
reaction mixture was diluted with MeOH and Amberlite IRC 50 was 
added until pH 7. The beads were filtered off and washed with 
MeOH, then, the filtrated solution was evaporated affording a crude 
reaction product (0.015  g). The solid product was dissolved in 
MeOH and filtered through a syringe filter. Evaporation of the 
solvent afforded a yellow solid, which was recrystallized from (i-
Pr)2O to yield fully O-deprotected 1,2-pseudomannobioside 5 (0.011 
g, 70 % yield), pure as a pale yellow solid: mp: 103-105 °C. Rf = 
0.15 (1:1 CH2Cl2/MeOH); [α]20D +16.4 (c 1.14, MeOH).  
FTIR (neat) ν 3396.5, 2924.9, 2852.6, 2746.5, 2489.3, 1537.7, 
1486.7, 1180.4, 1048.6, 1025.8 cm-1. 1H NMR (250 MHz, CD3OD) 
δ 5.06 (d, J = 1.7 Hz, 1H, Hanomeric), 4.03-4.11 (m, 1H, CHO), 
3.98 (dd, J = 3.2, 1.7 Hz, 1H, CHO), 3.42-3.93 (m, 12H, CHO), 3.13 
(t, J = 5.1 Hz, 2H, CH2NH2), 1.88-1.99 (m, 1H, H5), 1.53-1.85 (m, 
2H, H5aα + H5aβ). 13C NMR (63 MHz, CD3OD) δ 104.01, 96.65, 
79.60, 78.05, 75.52, 74.19, 72.49, 71.83, 68.75, 66.97, 64.47, 63.19, 
41.15, 40.46, 27.74. HRMS: (M +H+) found 384.1860; C15H30NO10 
requires 384.1870. 
3,4,6-tri-O-acetyl-1,2-anhydro-5a-carba-β-D-mannopyranose 
(13). 25 
β-Epoxide diol 11 (0,060g, 0.24 mmol, 1.0 equiv) was dissolved in 
EtOH (2.0 mL) and 10% Pd-C (0.010 g) was added. The reaction 
mixture was hydrogenated (1 bar) at room temperature under 
hydrogen saturated atmosphere overnight. The reaction mixture was 
then diluted with EtOH and filtered through a Celite® pad. The 
evaporation of the solvent afforded a crude reaction product which 
was further diluted with EtOH and filtered off using syringe filter, to 
remove the residue coal. Evaporation of the solvent afforded a crude 
reaction product (0.032 g) as a colorless liquid constituted by epoxy 
triol 12, directly acetylated. Epoxy triol 12 (0.032 g, 0.20 mmol, 1.0 
equiv) was dissolved in anhydous pyridine (0.5 mL) and the reaction 
mixture was cooled at 0°C. Acetic anhydride (0.25 mL) was added 
and the reaction was stirred at room temperature overnight. 
Coevaporation of the reaction mixture with toluene afforded a crude 
product (0.049 g), which was subjected to flash chromatography. 
Elution with 1:1 hexane/AcOEt mixture afforded tri-O-acetyl-β-
epoxide 13 (0.040 g, 70% yield), pure as a pale yellow oil. Rf = 0.26 
(hexane/AcOEt 1:1); 1H NMR (CDCl3) δ 5.23 (dd, J = 8.7, 1.8 Hz, 
1H, H3), 5.07-5.19 (m, 1H, H4), 4.05 (dd, J = 11.4, 4.9 Hz, 1H, H6), 
3.85 (dd, J = 11.3, 3.1 Hz, 1H, H6’), 3.41 (dd, J = 3.9, 1.5 Hz, 1H, 
H1), 3.33 (t, J = 4.2 Hz, 1H, H2), 2.13-2.25 (m, 1H, H5), 2.10 (s, 
3H, OAc), 2.04 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.88-1.97  (m, 2H, 
H5aα + H5aβ). 13C NMR (CDCl3) δ  171.11, 170.34, 170.02, 71.18, 
70.01, 69.90, 63.90, 53.38, 35.72, 29.20, 21.00, 20.96, 20.92. 
 
(2-azidoethyl)-3,4,6-tri-O-acetyl-5a-carba-α-D-mannopyranoside 
(15). 
Tri-O-acetyl epoxide 13 (0.033 g, 0.114 mmol, 1.0 equiv) was 
dissolved in a 1.3 M solution of 2-azido-1-ethanol in CH2Cl225 (0.36 
mL, 0.456 mmol, 4.0 equiv) and Cu(OTf)2 (0.016 g, 0.045 mmol, 
0.4 equiv) was added. The reaction mixture was stirred for 18 h at 
room temperature. Dilution with CH2Cl2 and evaporation of the 
washed (1:1 NaHCO3/NH4Cl mixture and brine) and dried 
(Na2SO4) organic solution afforded a crude reaction product (0.048 
g) which was subjected to flash chromatography. Elution with a 1:1 
hexane/AcOEt solution afforded the glycosyl acceptor 15 (0.035 g, 
82% yield), pure as a pale yellow oil. Rf = 0.14 (1:1 hexane/AcOEt). 
[α]20D +21.71 (c 0.35, CHCl3). FTIR (neat) ν 3480.4, 2956.7, 
2925.7, 2855.4, 2106.9, 1738.1, 1454.0, 1368.7, 1227.5, 1098.8, 
1039.6, 801.0 cm-1. 1H NMR (250 MHz, CDCl3) δ 5.23-5.34 (m, 
1H, H3), 5.20 (dd, J = 9.5, 2.7 Hz, 1H, H4), 4.16-4.23 (m, 1H, H2), 
4.11 (dd, J = 11.3, 4.9 Hz, 1H, H6), 3.94 (dd, J = 11.3, 4.9 Hz, 1H, 
H6’), 3.73-3.78 (m, 1H, H1), 3.70 (t, J = 5.0 Hz, 2H, CH2N3), 3.39 
(d, J = 4.6 Hz, 1H, OCH2), 3.35 (d, J = 4.6 Hz, 1H, OCH2), 2.24-
2.36 (m, 1H, H5), 2.08 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03 (s, 3H, 
OAc), 1.86-1.94 (m, 2H, H5aα + H5aβ). 13C NMR (CDCl3) δ 
171.13, 170.55, 169.90, 73.87, 69.71, 68.67, 63.93, 50.93, 35.19, 
26.77, 21.08, 20.96.  
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(2-azidoethyl)-2-O-[2’,3’,4’,6’-tetra-O-benzoyl-α-D-
mannopyranosyl]-3,4,6-tri-O-acetyl-5a-carba-α-D-
mannopyranoside (17). 
Trichloroacetimidate 621 (0.047g, 0.064 mmol, 1.3 equiv) and 
carbamannoside 15 (0.019 g, 0.049 mmol, 1.0 equiv) were dissolved 
in distilled toluene (2.0 mL) and dried overnight under vacuum. 
Acid washed molecular sieves AW 300 were activated under 
vacuum and added to the reagents. The mixture was dissolved in dry 
CH2Cl2 (1.0 mL) and a catalytic amount of TMSOTf (1.76 μL, 
0.010 mmol, 0.2 equiv) was added under nitrogen at -20°C and the 
reaction mixture was stirred at the same temperature for 20 minutes, 
monitoring by TLC (1:1 hexane/AcOEt ). Et3N (10.0 μL) was added 
and the mixture was diluted with CH2Cl2 and filtered through a 
Celite® pad. Evaporation of the solvent afforded a crude product 
(0.034 g), which was subjected to a flash chromatography. Elution 
with a 1:1 hexane/AcOEt mixture as eluent afforded the O-protected 
pseudomannobioside 17 (0.025 g, 53% yield) pure as a pale yellow 
oil. Rf = 0.40 (1:1 hexane/AcOEt). [α]20D -42.8 (c 1.7, CHCl3).  
1H NMR (CDCl3) δ 7.94-8.15 (m, 6H, Ar), 7.79-7.89 (m, 2H, Ar), 
7.21-7.67 (m, 12H, Ar), 6.06 (t, 1H, J = 9.9 Hz, H4’), 5.92 (dd, 1H, J 
= 10.2, 3.1 Hz, H2’), 5.69 (dd, 1H, J = 2.9, 1.6 Hz, H3’), 5.36 (d, 
1H, J = 10.1 Hz, H3), 5.32 (d, 1H, J = 1.6 Hz, Hanomeric), 5.26 (dd, 
1H, J = 9.8, 2.8 Hz, H4), 4.69 (dd, 1H, J = 12.0, 2.5 Hz, H6’a), 4.50 
(dd, 1H, J = 12.0, 5.4 Hz, H6’b), 4.36-4.45 (m, 1H, H5’), 4.31 (t, 
1H, J = 3.2 Hz, H2), 4.17 (dd, 1H, J = 11.4, 5.7 Hz, H6a), 4.03 (dd, 
1H, J = 11.4, 3.6 Hz, H6b), 3.73-3.80 (m, 1H, H1), 3.44-3.60 (m, 
2H, CH2N3), 3.13-3.36 (m, 2H, OCH2), 2.21-2.45 (m, 1H, H5), 
2.16 (s, 3H, OAc), 2.13 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.00 (dd, 
2H, J = 8.4, 2.3 Hz, H5aα + H5aβ). 13C NMR (CDCl3) δ 171.37, 
170.67, 170.06, 166.24, 165.81, 165.64, 165.31, 133.69, 133.39, 
130.00, 129.86, 129.43, 129.19, 128.98, 128.78, 128.63, 128.46, 
99.03, 76.32, 76.14, 72.44, 70.84, 69.96, 69.73, 69.26, 68.58, 67.45, 
63.85, 63.41, 50.80, 35.40, 20.94. 
 
(2-azidoethyl)-2-O-(α-D-mannopyranosyl)-5a-carba-α-D-
mannopyranoside (4). 
Compound 17 (0.025 g, 0.026 mmol, 1.0 equiv) was dissolved in 
MeOH (0.8 mL) and cooled at 0 °C. A freshly prepared 1.0 M 
solution of MeONa/MeOH (78 µL, 0.078 mmol, 0.3 equiv) was 
added to the resulting solution and the reaction mixture was stirred 
for 12 h at room temperature. The mixture was then neutralized with 
an acidic Amberlite™ IR 120 H resin The resin was then removed 
by filtration and repeatedly extracted with methanol. The combined 
filtrate was concentrated under vacuum to give a crude product, 
which was recrystallized from i-PrOH to yield pure glycoside 4 
(0.010 g, yield 88%) as a white solid: mp: 85-88°C. Rf = 0.21 (1:1 
CH2Cl2/MeOH). [α]20D -43.2 (c 0.36, MeOH) 1H NMR (D2O) δ 
4.98 (s, 1H, Hanomeric), 4.04 (bs, 2H, H1 + H2), 3.95 – 3.50 (m, 
12H, CHO, CH2O, CH2N3), 3.44 – 3.37 (m, 2H, OCH2), 1.96 – 
1.86 (m, 1H, H5), 1.80 – 1.54 (m, 2H, H5aα + H5aβ). 13C NMR 
(D2O, 0.1% CD3CN) δ 101.70, 78.45, 75.15, 72.81, 71.49, 69.51, 
69.23, 69.09, 66.77, 65.93, 61.30, 60.20, 49.57, 37.82, 25.40. 
HRMS: (M +Na+) found 432.1586; C15H27N3O10Na requires 
432.1594. 
Biological assays 
 
Surface plasmon resonance analysis. DC-SIGN ECD 
production and purification: DC-SIGN extracellular domain 
(DC-SIGN ECD) construct was produced and purified as 
described previously. 31  
Surface Plasmon Resonance analysis: Surface plasmon 
resonance experiments were performed on a Biacore 3000 
using a CM4 chip, functionalized at 5 μL/min.  BSA or BSA-
Man were immobilized on flow cells using amine-coupling 
method. Fc1 was prepared as reference surface. Flow cell (Fc) 1 
and 2 were activated with 50 μL of a 0.2M EDC/ 0.05 M NHS 
mixture. After this step, Fc1 and Fc2 were respectively 
functionalized with bovine serum albumine (BSA) and 
mannosylated bovine serum albumine (BSA-Mannotriose, 
BSA-manα1-3[manα1-6]man, 12 glycosylated sites, , 60 
µg.mL-1, Dextra laboratories). Then remaining activated 
groups of both cells were blocked with 30 μL of 1 M 
ethanolamine. After blocking, the two Fc were treated with 5 
μL of 10 mM HCl to remove unspecific bound protein and 5 μL 
of 50 mM EDTA to expose surface to regeneration protocol. 
Finally, 2381 RU and 1847 RU of BSA and BSA-Man were 
respectively immobilized on Fc1 and Fc2. The selected 
concentration was 20 μM for DC SIGN ECD. 
For inhibition studies, 20 M of DC-SIGN ECD mixed with 
increasing concentrations of inhibiting compounds were 
prepared in a running buffer composed of 25 mM Tris pH 8, 
150 mM NaCl, 4 mM CaCl2, 0.005% P20 surfactant, and 13 L 
of each sample was injected onto the surfaces at a 5 μL/min 
flow rate. The resulting sensorgrams were reference surface 
corrected. 
The DC-SIGN binding responses were extracted from 
sensorgrams, converted to percent residual activity values (y) 
with respect to lectin alone binding, and plotted against 
corresponding compound concentration. The 4-parameter 
logistic model (equation 1) was fitted to the plots, and the IC50 
values were calculated, from equation 2, using the values of 
fitted parameters (Rhi, Rlo, A1 and A2). 
              
Figure 4 Equation for percent residual activity values and for IC50 values   
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